Health
Designer DNA therapies shown to effectively target cancer stem cells – The Science Board
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human…
Multiple myeloma is the second most common blood cancer in the U.S. It generally recurs and is refractory (reoccurs and is unresponsive to treatments). Despite novel therapies, treatment toxicities continue to be a challenge for patients and clinicians.
In multiple myeloma, proinflammatory cytokines and antiviral interferons derived from bone marrow play a key role in disease progression, including activation of interleukin 6 (IL-6) with downstream interferon-response factor (IRF) signaling.
IRF4…
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News24 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
General23 hours ago307,000 Voices | The Spectator Australia
-
General23 hours agoLive and dead animals seized from Kyneton business after investigation